Loading...
Safe and effective treatments for migraine attacks remain an unmet need for many patients due to inadequate efficacy, contraindications, and tolerability issues. In particular, triptans, the current gold standard treatment for attacks, are contraindicated in patients with cardiovascular disease. Gepants are investigational small-molecule calcitonin gene–related peptide (CGRP) receptor antagonists that demonstrated efficacy in treating migraine attacks in proof-of-concept studies. Two manufacturer-funded, double-blinded, placebo-controlled phase 3 trials enrolling people with migraine with and without aura have now been conducted to evaluate the efficacy and safety of an oral formulation of ubrogepant in treating a single migraine attack.
In …